Argentine Hemorrhagic Fever (AHF)

Argentine hemorrhagic fever (AHF) is a serious viral illness caused by the Junín virus (a New World arenavirus). People usually get it after contact with infected field rodents in parts of Argentina. Illness often starts like the flu (fever, tiredness, body aches) and can progress in some patients to bleeding problems and nervous system symptoms. Without the right care early, the disease can be dangerous. The safest proven specific treatment is early immune (convalescent) plasma; otherwise, care is mostly supportive. PMC

Doctors describe three phases: a prodromal (early) phase with fever and malaise; a neurologic-hemorrhagic phase (in 20–30% of cases) with bleeding and neurologic signs; and convalescence. The incubation period is usually 6–14 days. Case-fatality in untreated patients historically reached 15–30%, but falls to ~1% with early immune plasma at proper antibody dose. PMC+2Canada.ca+2

Argentine hemorrhagic fever is a severe viral illness that happens in parts of Argentina. It is caused by the Junín virus, a member of the arenavirus family. People usually get infected when they breathe in dust or air that contains tiny particles of urine, droppings, or saliva from infected field mice (the reservoir rodent is Calomys musculinus). The disease often starts like the flu (fever, headache, body aches) and can progress to bleeding problems and brain or nerve symptoms. Without early, proper care, it can be deadly; with specific care given early, survival greatly improves. A live, single-dose vaccine called Candid#1 is used in Argentina to prevent disease in high-risk areas, and it led to a major drop in cases after its introduction. PubMed+4PMC+4PMC+4

Other names

• O’Higgins disease (named after the town linked to early reports). Wikipedia

• Mal de los rastrojos (“stubble disease”), a local name tied to exposure in crop stubble fields. Wikipedia

• Junín virus hemorrhagic fever (by cause/agent). PMC

AHF occurs in the Pampas region of Argentina, particularly in the provinces of Buenos Aires, Santa Fe, Córdoba, and La Pampa. People who farm, handle grain or hay, clean barns/silos, or work in rural fields are the most exposed. Risk rises during agricultural activities when dust is stirred up. Vaccination (Candid#1) greatly reduces risk in these areas. Person-to-person spread is rare but can occur in healthcare settings if body fluids are not handled safely. ICTV+3GOV.UK+3AG Salud+3

---

Types

You may see different “types” used in practice. These are not different viruses; they are ways of describing how the illness shows up or progresses.

1) By phase of illness

• Prodromal phase: The first week. Fever, headache, muscle aches, tiredness, facial flushing, red eyes, sore throat, nausea. Mild bleeding (like gum bleeding) may appear. Some people have tremor or unsteady walking. Wikipedia

• Neurologic–hemorrhagic phase: In a subset of patients around days 8–12. Worsening bleeding (nose, gums, gut, urine), confusion, seizures, severe weakness, low blood pressure. This phase is dangerous. Wikipedia

• Convalescent phase: Recovery. Fever settles, strength returns slowly. Some may have lingering weakness or mood changes for weeks.

2) By severity

• Mild: Fever and aches only; no bleeding; stable blood counts.

• Moderate: Bleeding signs on skin or mucosa, low platelets, but stable blood pressure.

• Severe (complicated): Major bleeding, shock, kidney or nervous system involvement.

3) By setting

• Community-acquired: From rodent exposure—most cases. PubMed

• Healthcare-associated (rare): From unprotected contact with a sick patient’s blood/body fluids. ICTV

---

Causes

Each “cause” below is a practical real-world situation that increases the chance of catching Junín virus.

1. Breathing dust contaminated with mouse droppings or urine in rural fields or barns. Tiny particles carry the virus into the lungs. PubMed

2. Working in crop stubble (“rastrojos”) after harvest, which stirs up contaminated dust. Wikipedia

3. Cleaning or sweeping closed storerooms, silos, or sheds without wetting the floor first, which aerosolizes rodent excreta. PubMed

4. Handling or storing grain, hay, or animal feed that attracts reservoir rodents. De Gruyter Brill

5. Living or working near field borders and hedgerows where Calomys musculinus prefers to move and nest. ScienceDirect

6. Not being vaccinated (Candid#1) if you live/work in the endemic zone. Vaccination is protective. PubMed+1

7. Peak agricultural seasons when human–rodent contact and dusty work increase. Wikipedia

8. Poor rodent control in homes, barns, and grain stores. More mice means more viral shedding. DigitalCommons UNL

9. Sleeping or eating in rodent-infested structures (exposure to droppings on surfaces). DigitalCommons UNL

10. Handling live or dead rodents without gloves or masks. ICTV

11. Healthcare exposure without proper PPE (rare person-to-person via body fluids). ICTV

12. Laboratory exposure to Junín virus without high-level biosafety and vaccination (JUNV is a high-containment agent). Oxford Academic

13. Staying or working in hyper-endemic pockets within the Pampas (hotspot areas). ResearchGate

14. Wild rodent population booms after favorable climate or food conditions, increasing environmental contamination. scielo.org.ar

15. Stirring dry nesting material when clearing fields or sheds. PubMed

16. Travel to the endemic provinces (Buenos Aires, Santa Fe, Córdoba, La Pampa) for fieldwork without precautions. GOV.UK

17. Living in rural settlements with unsealed grain storage that attracts mice. De Gruyter Brill

18. Burning or mowing thick field edges that serve as rodent corridors. ScienceDirect

19. Not wet-mopping before cleaning dusty spaces (dry sweeping aerosolizes virus). PubMed

20. Ignoring early symptoms and continuing heavy farm work, leading to higher exposure for coworkers and delayed care.

---

Symptoms

1. Fever: Often sudden. It is the body’s response to the virus. Wikipedia

2. Severe tiredness (fatigue): Common early; daily tasks feel heavy. Wikipedia

3. Headache: Diffuse head pain that worsens with fever. Wikipedia

4. Muscle and back pain: Achy, flu-like soreness, especially low back. Wikipedia

5. Eye pain and red eyes (conjunctival injection): Eyes look bloodshot and feel sore. Wikipedia

6. Nausea or vomiting: The gut is irritated; eating is hard. Wikipedia

7. Facial flushing: The face looks unusually red early on. Wikipedia

8. Sore throat: Irritation of the mouth and throat lining. Wikipedia

9. Small skin bleeds (petechiae) or easy bruising: From low platelets and fragile vessels. Wikipedia

10. Bleeding from gums or nose (epistaxis): A warning of hemorrhagic involvement. Wikipedia

11. Dizziness or faint feeling: From dehydration or low blood pressure.

12. Unsteady walking (ataxia) or tremor: Virus and inflammation affect the nervous system. Wikipedia

13. Confusion or drowsiness: Brain involvement in severe disease. Wikipedia

14. Shortness of breath: Can occur with severe illness or secondary infections.

15. Worsening bleeding (vomiting blood, bloody urine, black stools): Emergency signs needing urgent care.

---

Diagnostic tests

A) Physical examination (bedside findings)

1. Vital signs check (temperature, pulse, blood pressure, breathing): Confirms fever, looks for fast pulse or low pressure that signal severe disease.

2. Skin and mucosa exam: Doctors look for petechiae, bruises, gum or nose bleeding—classic hemorrhagic signs. Wikipedia

3. Eye exam: Red conjunctiva supports the clinical picture; also checks for bleeding spots. Wikipedia

4. Neurologic exam: Tests balance, speech, reflexes, and mental state to detect tremor, ataxia, or confusion. Wikipedia

5. Hydration and shock assessment (capillary refill, skin turgor): Finds early dehydration or poor perfusion.

B) “Manual” or bedside tests/procedures

6. Orthostatic blood pressure measurement: Drop in pressure when standing suggests volume loss or early shock.

7. Bedside stool occult blood test: Detects hidden gut bleeding.

8. Point-of-care hemoglobin/hematocrit: Quick check for bleeding or hemoconcentration.

9. Finger-stick glucose: Hypoglycemia can worsen confusion; easy to correct.

10. Pulse oximetry: Low oxygen saturation suggests severe illness or lung involvement.

C) Laboratory and pathological tests (core to diagnosis and monitoring)

11. Complete blood count (CBC): Often shows low white blood cells and low platelets, which match hemorrhagic risks. Medcoe Cloud Storage

12. Coagulation tests (PT/INR, aPTT, fibrinogen, D-dimer): Check clotting problems that drive bleeding.

13. Liver function tests (ALT, AST, bilirubin): Look for liver stress from the infection.

14. Kidney function tests (creatinine, urea): Assess dehydration, shock, or kidney involvement.

15. Inflammation markers (CRP) and bacterial cultures if needed: Rule out bacterial co-infection in very sick patients.

16. Virus-specific RT-PCR for Junín virus (blood): Detects viral genetic material early; fast and specific. (This was shown feasible for AHF and is a modern standard.) PubMed+1

17. Junín virus serology (IgM/IgG ELISA): IgM suggests recent infection; IgG rise between paired samples confirms diagnosis. Medcoe Cloud Storage

18. Virus isolation (culture) in high-containment lab: A reference test but used sparingly due to biosafety; reserved for specialized centers. Oxford Academic

D) Electrodiagnostic tests (to assess complications)

19. Electrocardiogram (ECG): Checks heart rhythm and signs of low blood flow or stress in severe cases.

20. Electroencephalogram (EEG): Used if seizures or confusion occur to evaluate brain function during the neurologic–hemorrhagic phase. Wikipedia

E) Imaging (used when indicated)

• Chest X-ray: Looks for pneumonia, fluid, or bleeding-related lung issues.

• Abdominal ultrasound: Checks liver, spleen, and bleeding into the abdomen if suspected.

• Head CT/MRI (if severe neurologic signs): Excludes brain bleeding or other emergencies.

Non-pharmacological treatments

Note: For AHF, supportive care and infection-control are the backbone of management. These therapies help your body while specific treatment (immune plasma) and careful monitoring are provided. I explain purpose and mechanism briefly for each.

1. Strict isolation & PPE use.
   Purpose: Protect healthcare workers and family from body-fluid exposure.
   Mechanism: Barriers (gowns, gloves, eye/face protection) and dedicated rooms reduce virus spread during procedures and cleaning. CDC

2. Early triage & monitoring.
   Purpose: Detect warning signs (bleeding, confusion, low blood pressure).
   Mechanism: Frequent vital-sign checks and labs guide timely fluids, transfusion, and plasma therapy. CDC+1

3. Fluid resuscitation (oral or IV).
   Purpose: Correct dehydration and maintain blood pressure.
   Mechanism: Oral rehydration or isotonic IV fluids restore intravascular volume and electrolytes. WHO Apps+1

4. Electrolyte replacement.
   Purpose: Fix low sodium, potassium, or other salts that affect heart/brain.
   Mechanism: Measured replacement prevents arrhythmia and seizures. PMC

5. Temperature control without NSAIDs.
   Purpose: Reduce fever safely.
   Mechanism: Use physical cooling and acetaminophen (paracetamol) rather than NSAIDs that worsen bleeding. NCBI

6. Bleeding-risk minimization.
   Purpose: Lower hemorrhage risk.
   Mechanism: Avoid intramuscular injections, minimize needles, and use soft toothbrushes and gentle care. CDC

7. Oxygen therapy.
   Purpose: Support patients with low oxygen.
   Mechanism: Nasal cannula or mask improves tissue oxygen delivery in shock or lung involvement. CDC

8. Nutrition support.
   Purpose: Maintain strength and healing.
   Mechanism: Small frequent feeds or enteral nutrition with adequate protein and calories as tolerated. WHO Apps

9. Nausea/vomiting control (non-drug measures + safe meds).
   Purpose: Prevent dehydration and aspiration.
   Mechanism: Positioning, slow sips; add antiemetics if needed (see drug section). efashare.b-cdn.net

10. Seizure precautions.
    Purpose: Protect airway and prevent injury if neurologic symptoms occur.
    Mechanism: Side-lying position, suction readiness; add anticonvulsants if seizures. WHO Apps

11. Careful blood draw strategy.
    Purpose: Reduce bleeding events.
    Mechanism: Draw only essential labs with smallest feasible needles and prolonged pressure afterward. CDC

12. Transfusion planning (with lab guidance).
    Purpose: Treat significant bleeding or thrombocytopenia.
    Mechanism: Platelets, plasma, or red cells as per bleeding and counts (immune plasma is specific therapy—see drugs). WHO Apps

13. Renal support readiness.
    Purpose: Manage kidney failure if it develops.
    Mechanism: Dialysis accessibility and strict fluid balance. Mayo Clinic

14. Delirium/confusion care.
    Purpose: Keep patient safe.
    Mechanism: Reorientation, low-stimulus environment; medications only if necessary (see drugs). WHO Apps

15. Avoid unnecessary procedures.
    Purpose: Lower exposure and bleeding risks.
    Mechanism: Defer aerosol-generating or invasive procedures unless life-saving. CDC

16. Infection-prevention cleaning protocols.
    Purpose: Decontaminate surfaces and equipment.
    Mechanism: Use recommended disinfectants; careful waste handling. CDC

17. Hemodynamic monitoring.
    Purpose: Guide fluids and vasopressors in shock.
    Mechanism: Frequent blood pressure, urine output, and mental-status assessment. CDC

18. Psychological support.
    Purpose: Reduce anxiety and improve cooperation with care.
    Mechanism: Clear communication; allow remote family contact. WHO Apps

19. Early consultation with public health.
    Purpose: Coordinate testing, contact tracing, and safe transfer.
    Mechanism: Notify health authorities/CDC; follow transport and lab safety steps. CDC

20. Vaccination (pre-exposure, endemic areas).
    Purpose: Prevent disease in at-risk adults.
    Mechanism: Candid#1 live vaccine induces neutralizing antibodies; reduces AHF incidence in endemic provinces. PubMed+1

---

Drug treatments

Important: Only one disease-specific therapy has strong human evidence—early immune plasma with adequate neutralizing antibody dose. Other medicines are supportive or investigational. I list each with class, typical dosing or use, timing, purpose, mechanism, and key side effects where known.

1. Immune (convalescent) plasma – Specific antiviral passive immunotherapy
   Class: Antibody-based therapy.
   Dose/Time: Transfuse early (within 8 days of symptom onset) with ≥3,000 therapeutic units/kg of neutralizing antibodies (dose expressed per kg based on antibody titer in units).
   Purpose: Rapidly neutralize Junín virus and prevent progression.
   Mechanism: Donor antibodies bind virus, limiting viremia and organ damage.
   Side effects: Transfusion reactions (rare), volume overload—monitor closely. In trials and large cohorts, mortality decreased to ~1% vs ~15–30% untreated when given early at adequate dose. PubMed+2PMC+2

2. Ribavirin (investigational/adjunct in AHF; proven for some arenaviruses)
   Class: Broad-spectrum antiviral (nucleoside analogue).
   Dose/Time: No standardized AHF regimen; used compassionately, especially after day 8 or when plasma unavailable; dosing modeled on Lassa fever protocols under expert guidance.
   Purpose: Reduce viral replication when immune plasma is delayed or not feasible.
   Mechanism: Inhibits viral RNA synthesis.
   Side effects: Hemolytic anemia, teratogenicity; monitor CBC. Evidence in AHF is limited (small human series; animal studies positive but less than favipiravir). Infectious Diseases Journal+2ScienceDirect+2

3. Favipiravir (T-705) (experimental)
   Class: RNA-dependent RNA polymerase inhibitor.
   Dose/Time: No approved AHF dose; used compassionately in one imported case alongside ribavirin.
   Purpose: Potential antiviral effect when plasma is unavailable/late.
   Mechanism: Lethal mutagenesis of RNA viruses; strong protection in a guinea-pig Junín model.
   Side effects: Hyperuricemia, GI upset; teratogenic in animals. Human AHF data limited to case report. PLOS+1

4. Acetaminophen (paracetamol)
   Class: Antipyretic/analgesic.
   Dose/Time: 500–1,000 mg orally every 6–8 h (max 3–4 g/day; adjust for liver disease).
   Purpose: Fever and pain control without raising bleeding risk.
   Mechanism: Central COX inhibition; antipyretic.
   Side effects: Hepatotoxicity in overdose; avoid combining with alcohol. Avoid NSAIDs/aspirin due to bleeding. NCBI

5. Ondansetron
   Class: Antiemetic (5-HT3 antagonist).
   Dose/Time: 4–8 mg orally/IV every 8–12 h as needed.
   Purpose: Control vomiting to prevent dehydration.
   Mechanism: Blocks serotonin receptors in gut/brain.
   Side effects: Headache, constipation; rare QT prolongation—monitor if risk. efashare.b-cdn.net

6. Proton pump inhibitor (e.g., pantoprazole)
   Class: Acid suppression.
   Dose/Time: 40 mg IV/PO daily.
   Purpose: Stress-ulcer prophylaxis in critically ill to reduce GI bleeding risk.
   Mechanism: Inhibits gastric H+/K+ ATPase.
   Side effects: Headache; long-term risks not relevant short-term. WHO Apps

7. Tranexamic acid (use cautiously; not routine in VHFs)
   Class: Antifibrinolytic.
   Dose/Time: If life-threatening bleeding and specialist advises, e.g., 1 g IV once; individualized.
   Purpose: Stabilize clots in severe hemorrhage.
   Mechanism: Blocks plasminogen activation.
   Side effects: Thrombosis risk; must weigh against DIC/bleeding patterns in VHFs. Evidence in AHF is not established—specialist decision only. WHO Apps

8. Platelet transfusion (blood product, but part of drug therapy bundle)
   Class: Hemostatic component therapy.
   Dose/Time: As per counts/bleeding.
   Purpose: Treat thrombocytopenia with active bleeding or procedures.
   Mechanism: Replaces platelets to form clots.
   Side effects: Transfusion reactions. WHO Apps

9. Fresh frozen plasma (non-immune)
   Class: Coagulation factor replacement.
   Dose/Time: Based on INR/bleeding.
   Purpose: Correct coagulopathy when bleeding.
   Mechanism: Supplies clotting factors.
   Side effects: Volume overload; TRALI risk—monitor. WHO Apps

10. Packed red blood cells
    Class: Oxygen-carrying replacement.
    Dose/Time: Per hemoglobin and symptoms.
    Purpose: Treat significant anemia from bleeding.
    Mechanism: Restores oxygen delivery.
    Side effects: Transfusion reactions. WHO Apps

11. Norepinephrine
    Class: Vasopressor.
    Dose/Time: Titrate IV infusion for shock unresponsive to fluids.
    Purpose: Maintain blood pressure and organ perfusion.
    Mechanism: α-adrenergic vasoconstriction.
    Side effects: Arrhythmias, ischemia—ICU monitoring required. CDC

12. Broad-spectrum antibiotics (empiric, if bacterial coinfection suspected)
    Class: Antibacterials (not antiviral).
    Dose/Time: Empiric per sepsis protocols if bacterial infection cannot be excluded.
    Purpose: Treat possible secondary bacterial infection; does not treat AHF itself.
    Mechanism: Kills bacteria; chosen by local guidelines.
    Side effects: Drug-specific; steward use. CDC

13. Levetiracetam
    Class: Anticonvulsant.
    Dose/Time: 500–1,000 mg twice daily; IV loading in status.
    Purpose: Control seizures in neurologic phase.
    Mechanism: Modulates synaptic vesicle protein (SV2A).
    Side effects: Somnolence, mood changes. WHO Apps

14. Chlorpromazine (for hiccups/intractable nausea in VHF guidance lists)
    Class: Antidopaminergic antiemetic.
    Dose/Time: 25 mg twice daily (example adult standing order in VHF guides).
    Purpose: Relieve distressing hiccups/nausea.
    Mechanism: Dopamine receptor blockade.
    Side effects: Sedation, hypotension—monitor. efashare.b-cdn.net

15. Benzodiazepines (e.g., lorazepam)
    Class: Anxiolytic/anticonvulsant.
    Dose/Time: 1–2 mg IV/PO as needed for agitation/seizure.
    Purpose: Control severe agitation or seizure activity.
    Mechanism: GABA-A receptor modulation.
    Side effects: Respiratory depression—use carefully. WHO Apps

16. Thiamine (vitamin B1)
    Class: Vitamin cofactor.
    Dose/Time: 100 mg IV/PO daily (critical-illness norm).
    Purpose: Prevent Wernicke’s and support metabolism during poor intake.
    Mechanism: Cofactor in carbohydrate metabolism.
    Side effects: Very safe; rare allergy. WHO Apps

17. Insulin (if stress hyperglycemia)
    Class: Antihyperglycemic.
    Dose/Time: ICU protocol.
    Purpose: Maintain glycemic control; hyperglycemia worsens outcomes in critical illness.
    Mechanism: Increases glucose uptake.
    Side effects: Hypoglycemia—protocolized monitoring. WHO Apps

18. Antidiarrheals (use cautiously)
    Class: Symptomatic.
    Dose/Time: Avoid if blood in stool/fever—risk of complications.
    Purpose: Only if advised to reduce fluid losses.
    Mechanism: Slows gut motility.
    Side effects: Ileus; follow clinician advice. WHO Apps

19. Analgesic adjuncts (topicals/low-risk agents)
    Class: Local analgesics.
    Dose/Time: As needed.
    Purpose: Pain relief without systemic bleeding risk.
    Mechanism: Local effect.
    Side effects: Minimal if used appropriately. WHO Apps

20. Vaccination with Candid#1 (public health tool, not treatment)
    Class: Live attenuated vaccine.
    Dose/Time: Pre-exposure in endemic regions for eligible adults.
    Purpose: Prevent future AHF.
    Mechanism: Induces neutralizing antibodies.
    Side effects: Generally well tolerated; robust seroconversion. PubMed

---

Dietary molecular supplements

There is no supplement proven to treat AHF. Nutrition aids recovery but must never delay plasma or hospital care. Use only under clinician guidance.

1. Oral rehydration salts (ORS).
   Dose: Per packet instructions.
   Function/Mechanism: Replace water, sodium, potassium, and glucose to prevent dehydration. WHO Apps

2. Electrolyte solutions (medical-grade).
   Dose: As prescribed.
   Function: Correct electrolyte losses; support nerve and muscle function. PMC

3. Multivitamin with minerals.
   Dose: Daily standard dose.
   Function: Covers micronutrient gaps during poor intake. WHO Apps

4. Thiamine (B1).
   Dose: 100 mg/day (see above).
   Function: Supports carbohydrate metabolism during illness. WHO Apps

5. Folate & B-complex (if deficient diet).
   Dose: Standard daily dose.
   Function: Support hematopoiesis and tissue repair. WHO Apps

6. Protein supplements (medical drinks).
   Dose: As dietician prescribes.
   Function: Preserve lean mass and immune function. WHO Apps

7. Zinc (only if deficient; don’t exceed RDA).
   Dose: Typical 10–20 mg/day short-term.
   Function: General immune cofactor; no AHF-specific data. WHO Apps

8. Vitamin C (RDA-level).
   Dose: Dietary amounts; avoid megadoses.
   Function: Antioxidant; no proof for AHF outcomes. WHO Apps

9. Vitamin D (if deficient).
   Dose: As per local guidelines.
   Function: Immune modulation in deficiency; no AHF-specific trials. WHO Apps

10. Probiotics (caution).
    Dose: As advised; avoid in severe immunocompromise.
    Function: Gut support during recovery; no AHF-specific benefit proven. WHO Apps

---

Immunity booster / regenerative / stem-cell drugs

There are no approved “immunity booster,” regenerative, or stem-cell drugs for AHF. The safest and proven disease-specific therapy is immune plasma. The items below explain what’s discussed in research or critical-care practice; none replace plasma/supportive care.

1. Convalescent immune plasma (passive immunotherapy).
   Dose: Early; ≥3,000 units/kg antibody.
   Function/Mechanism: Provides ready-made neutralizing antibodies to clear virus. PubMed

2. Favipiravir (experimental antiviral).
   Dose: Case-by-case; research setting.
   Function: Inhibits viral polymerase; strong animal data for Junín. PLOS

3. Ribavirin (adjunct, limited AHF evidence).
   Dose: Specialist protocol.
   Function: Broad antiviral that may reduce replication. Infectious Diseases Journal

4. IV immunoglobulin (IVIG) (not standard).
   Dose: Only in specific immune issues.
   Function: General passive immunity; not AHF-specific. CDC

5. Recombinant coagulation factors (e.g., fibrinogen concentrate) in bleeding.
   Dose: Specialist hemostasis protocols.
   Function: Replace missing factors to aid clotting; not antiviral. WHO Apps

6. No stem-cell therapy is recommended.
   Dose: —
   Function: No evidence for AHF; avoid outside trials. CDC

---

Surgeries

Surgery is not standard for AHF. If a life-threatening complication occurs, procedures may be considered:

1. Central venous catheter placement for ICU infusions if necessary, using maximum precautions to limit bleeding and exposure. Why: Secure access when peripheral IVs fail. CDC

2. Dialysis catheter insertion if acute kidney failure requires hemodialysis; done with strict bleeding control. Why: Renal replacement therapy. Mayo Clinic

3. Endoscopic hemostasis only if severe GI bleeding; risks must be weighed carefully. Why: Control focal bleeding source. WHO Apps

4. Airway procedures (intubation) when respiratory failure or airway protection is needed; employ aerosol and exposure precautions. Why: Life-saving ventilation. CDC

5. Surgical control of external hemorrhage (packing/ligation) as last resort. Why: Stop uncontrolled bleeding when conservative measures fail. WHO Apps

---

Preventions

1. Vaccination (Candid#1) for eligible adults in endemic provinces. PubMed

2. Avoid rodent exposure in rural fields; use gloves and sealed footwear.

3. Seal food and grain to deter rodents in homes/silos.

4. Environmental hygiene: safe cleaning of rodent droppings (avoid sweeping dry; dampen first). CDC

5. PPE at work: masks and eye protection when disturbing dusty barns/fields. CDC

6. Prompt care if sick after exposure—seek medical help early (within days). CDC

7. No NSAIDs/aspirin if febrile after exposure unless a clinician approves. NCBI

8. Household isolation precautions if a case is suspected—separate utensils, laundry caution. CDC

9. Healthcare facility preparedness (trained teams, checklists). ASPR TRACIE

10. Public health notification for suspected cases to coordinate testing and contacts. CDC

---

When to see doctors

• Immediately if you live in/traveled to endemic areas and develop fever, severe tiredness, body aches, nausea, or bleeding (gums, nose, urine, stool). Early evaluation allows immune plasma within the optimal window (first week). PMC

• Urgently for confusion, fainting, severe vomiting/diarrhea, or trouble breathing—these can be warning signs of progression and shock. WHO Apps

• Anytime after exposure if you’re pregnant, elderly, immunocompromised, or have chronic illness—risk may be higher; seek tailored advice. CDC

---

What to eat / what to avoid

• Drink ORS or clear fluids often to prevent dehydration; small sips if nauseated. WHO Apps

• Eat soft, easy foods (rice, soups, bananas, yogurt) as tolerated. WHO Apps

• Include adequate protein (eggs, lentils, dairy) for healing when you can eat. WHO Apps

• Avoid alcohol—adds liver stress and interacts with medicines like acetaminophen. NCBI

• Avoid herbal/botanical products that increase bleeding (e.g., ginkgo, high-dose garlic) unless a clinician approves. WHO Apps

• Avoid NSAIDs/aspirin for pain/fever unless your clinician tells you otherwise; use acetaminophen. NCBI

• Sip ginger or mint tea for nausea (adjunct only). efashare.b-cdn.net

• Resume regular balanced meals slowly; small frequent portions are easier early on. WHO Apps

• Check any supplement with your care team—none replace plasma or hospital care. CDC

• Follow exact dietary and hydration advice from your clinicians based on labs and symptoms. WHO Apps

---

FAQs

1) What causes AHF?
A virus called Junín virus carried by certain field rodents in parts of Argentina.

2) How long after exposure do symptoms start?
Usually 6–14 days. PMC

3) What are the first symptoms?
Fever, tiredness, headache, muscle aches, nausea; sometimes eye redness and mild bleeding. PMC

4) Can it become severe?
Yes—about 20–30% develop bleeding and neurologic problems around days 8–12. Canada.ca

5) How is AHF diagnosed?
By specialized lab tests (PCR/serology) in high-safety labs; clinicians also use exposure history and exam. CDC

6) What treatment really works best?
Early immune plasma with enough neutralizing antibodies; it cut mortality to ~1% in studies when given within 8 days. PubMed+1

7) Are there antiviral pills?
No approved antivirals for AHF. Ribavirin and favipiravir have limited human data (some animal/case evidence); use is specialist-guided. Infectious Diseases Journal+1

8) Is there a vaccine?
Yes—Candid#1 in Argentina for at-risk adults; it reduces cases but is not widely licensed elsewhere. PubMed+1

9) Can I take ibuprofen or aspirin?
Avoid them unless your doctor says otherwise because they can increase bleeding. Prefer acetaminophen. NCBI

10) Is it contagious person-to-person?
Main risk is exposure to blood/body fluids in healthcare settings; standard VHF precautions are required. Household airborne spread is not the main route. CDC

11) What happens in the hospital?
You’ll receive isolation precautions, fluids, monitoring, blood products if needed, and immune plasma early if eligible. WHO Apps

12) Why is early care so important?
Because immune plasma works best in the first week, before severe complications start. PMC

13) Can children get AHF?
Yes, but vaccination and risk vary by location/eligibility; management principles are similar and specialist-led. CDC

14) I work in the fields—what should I do?
Get local advice on Candid#1 vaccination if eligible, use rodent control, PPE for dusty areas, and seek care fast if sick. PubMed

15) Where can clinicians find detailed guidance?
See the CDC/PAHO/WHO documents on clinical management of VHFs and AHF specifically. CDC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 21, 2025.